Do KT, Kochupurakkal B, Kelland S, de Jonge A, et al. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Clin Cancer Res 2021;27:4710-4716.
PMID: 34131002